_version_ 1783703876847796224
author Murray, Heather C.
Enjeti, Anoop K.
Kahl, Richard G. S.
Flanagan, Hayley M.
Sillar, Jonathan
Skerrett-Byrne, David A.
Al Mazi, Juhura G.
Au, Gough G.
de Bock, Charles E.
Evans, Kathryn
Smith, Nathan D.
Anderson, Amanda
Nixon, Brett
Lock, Richard B.
Larsen, Martin R.
Verrills, Nicole M.
Dun, Matthew D.
author_facet Murray, Heather C.
Enjeti, Anoop K.
Kahl, Richard G. S.
Flanagan, Hayley M.
Sillar, Jonathan
Skerrett-Byrne, David A.
Al Mazi, Juhura G.
Au, Gough G.
de Bock, Charles E.
Evans, Kathryn
Smith, Nathan D.
Anderson, Amanda
Nixon, Brett
Lock, Richard B.
Larsen, Martin R.
Verrills, Nicole M.
Dun, Matthew D.
author_sort Murray, Heather C.
collection PubMed
description
format Online
Article
Text
id pubmed-8179851
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81798512021-06-17 Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia Murray, Heather C. Enjeti, Anoop K. Kahl, Richard G. S. Flanagan, Hayley M. Sillar, Jonathan Skerrett-Byrne, David A. Al Mazi, Juhura G. Au, Gough G. de Bock, Charles E. Evans, Kathryn Smith, Nathan D. Anderson, Amanda Nixon, Brett Lock, Richard B. Larsen, Martin R. Verrills, Nicole M. Dun, Matthew D. Leukemia Letter Nature Publishing Group UK 2020-10-16 2021 /pmc/articles/PMC8179851/ /pubmed/33067575 http://dx.doi.org/10.1038/s41375-020-01050-y Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Letter
Murray, Heather C.
Enjeti, Anoop K.
Kahl, Richard G. S.
Flanagan, Hayley M.
Sillar, Jonathan
Skerrett-Byrne, David A.
Al Mazi, Juhura G.
Au, Gough G.
de Bock, Charles E.
Evans, Kathryn
Smith, Nathan D.
Anderson, Amanda
Nixon, Brett
Lock, Richard B.
Larsen, Martin R.
Verrills, Nicole M.
Dun, Matthew D.
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
title Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
title_full Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
title_fullStr Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
title_full_unstemmed Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
title_short Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
title_sort quantitative phosphoproteomics uncovers synergy between dna-pk and flt3 inhibitors in acute myeloid leukaemia
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179851/
https://www.ncbi.nlm.nih.gov/pubmed/33067575
http://dx.doi.org/10.1038/s41375-020-01050-y
work_keys_str_mv AT murrayheatherc quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT enjetianoopk quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT kahlrichardgs quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT flanaganhayleym quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT sillarjonathan quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT skerrettbyrnedavida quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT almazijuhurag quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT augoughg quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT debockcharlese quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT evanskathryn quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT smithnathand quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT andersonamanda quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT nixonbrett quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT lockrichardb quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT larsenmartinr quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT verrillsnicolem quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia
AT dunmatthewd quantitativephosphoproteomicsuncoverssynergybetweendnapkandflt3inhibitorsinacutemyeloidleukaemia